![Hans Ivar Robinson](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Hans Ivar Robinson
Vorstandsvorsitzender bei
Birk Venture AS
Profil
Hans Ivar Robinson is the founder of Birk Venture AS, founded in 2010, serving as Managing Director & Chairman since its founding.
Mr. Robinson is the founder of Zelluna Immunotherapy AS, founded in 2016, serving as Non-Executive Officer since 2024.
Current jobs include Chairman at Nextera AS since 2010 and Director at Accession Therapeutics Ltd. Former jobs include Non-Executive Director at Oncoinvent ASA, Director at APIM Therapeutics AS, Director at Circio Holding ASA, Director at Zelluna ASA from 2025 to 2026, Principal at AstraZeneca AS, Vice President-Investor Relations at Pronova BioPharma ASA in 2009, and Principal at Pfizer AS.
Education includes graduate studies at the Norwegian School of Economics & Business Administration.
Aktive Positionen von Hans Ivar Robinson
| Unternehmen | Position | Beginn |
|---|---|---|
Birk Venture AS
 Birk Venture AS Investment ManagersFinance Birk Venture is an active manager which makes strategic, long-term investments in life science companies in the pharmaceutical, biotechnology, diagnostics, medical devices and instruments and consumer health sectors. Their geographic focus is on Scandinavia. The firm seeks to identify small-sized listed and unlisted start-up companies with the potential to be public within one to two years which have significant growth prospects, a unique technology and significant market potential. They prefer to invest in companies that have an attractive long-term business case, partnering with entrepreneurs and co-investors to fully exploit the market potential offered by the investee company's new technologies. Through board memberships or direct involvement in specific strategic projects, Birk Venture provides investee companies with a range of internal and external resources including management, sales & marketing, business development, licensing, intellectual property and product portfolio management. | Vorstandsvorsitzender | 05.02.2010 |
Nextera AS
 Nextera AS Miscellaneous Commercial ServicesCommercial Services Provides drug research for therapeutic interventions for autoimmune diseases, chronic infections, and cancer | Vorsitzender | 01.01.2010 |
Zelluna Immunotherapy AS
 Zelluna Immunotherapy AS BiotechnologyHealth Technology Engages in development of off the shelf T-cell receptor natural killer cell therapies | Gründer | 01.01.2016 |
Accession Therapeutics Limited
 Accession Therapeutics Limited BiotechnologyHealth Technology Develops novel immuno-oncology therapeutics | Direktor/Vorstandsmitglied | - |
Ehemalige bekannte Positionen von Hans Ivar Robinson
| Unternehmen | Position | Ende |
|---|---|---|
Pronova BioPharma ASA
 Pronova BioPharma ASA Pharmaceuticals: OtherHealth Technology Develops, manufactures and markets omega-3-derived pharmaceuticals | Public Communications Contact | 01.12.2009 |
| CIRCIO HOLDING ASA | Direktor/Vorstandsmitglied | - |
Pfizer AS
 Pfizer AS Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops medicines | Corporate Officer/Principal | - |
AstraZeneca AS | Corporate Officer/Principal | - |
Ausbildung von Hans Ivar Robinson
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
31
Beziehungen ersten Grades
11
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 11 |
|---|---|
AstraZeneca AS | |
Pronova BioPharma ASA
Pronova BioPharma ASA Pharmaceuticals: OtherHealth Technology Develops, manufactures and markets omega-3-derived pharmaceuticals | Health Technology |
Norwegian School of Economics & Business Administration
 Norwegian School of Economics & Business Administration Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Nextera AS
Nextera AS Miscellaneous Commercial ServicesCommercial Services Provides drug research for therapeutic interventions for autoimmune diseases, chronic infections, and cancer | Commercial Services |
Pfizer AS
Pfizer AS Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company which develops medicines | Health Technology |
BerGenBio ASA
 BerGenBio ASA Pharmaceuticals: MajorHealth Technology Develops drugs for aggressive, drug resistant cancers | Health Technology |
APIM Therapeutics AS
 APIM Therapeutics AS Pharmaceuticals: MajorHealth Technology Develops and commercializes novel anti-cancer therapies | Health Technology |
Birk Venture AS
Birk Venture AS Investment ManagersFinance Birk Venture is an active manager which makes strategic, long-term investments in life science companies in the pharmaceutical, biotechnology, diagnostics, medical devices and instruments and consumer health sectors. Their geographic focus is on Scandinavia. The firm seeks to identify small-sized listed and unlisted start-up companies with the potential to be public within one to two years which have significant growth prospects, a unique technology and significant market potential. They prefer to invest in companies that have an attractive long-term business case, partnering with entrepreneurs and co-investors to fully exploit the market potential offered by the investee company's new technologies. Through board memberships or direct involvement in specific strategic projects, Birk Venture provides investee companies with a range of internal and external resources including management, sales & marketing, business development, licensing, intellectual property and product portfolio management. | Finance |
Circio Holding ASA
 Circio Holding ASA BiotechnologyHealth Technology Develops active immunotherapy cancer vaccines | Health Technology |
Zelluna Immunotherapy AS
Zelluna Immunotherapy AS BiotechnologyHealth Technology Engages in development of off the shelf T-cell receptor natural killer cell therapies | Health Technology |
Accession Therapeutics Limited
Accession Therapeutics Limited BiotechnologyHealth Technology Develops novel immuno-oncology therapeutics | Health Technology |
